Leadership Appointments at Resolution Therapeutics
Resolution Therapeutics is excited to announce the appointment of Lucy Singah as Chief Financial Officer (CFO) and Daniel Kennedy as Chief Business Officer (CBO). These strategic appointments are expected to play a significant role in driving the company's corporate and strategic goals, especially in the realm of regenerative therapies aimed at inflammatory and fibrotic diseases.
Introducing the New Chief Financial Officer
With over two decades of experience in corporate finance across both the UK and the US, Lucy Singah is poised to lead the financial strategies at Resolution. Having served as CFO at Echopoint Medical, Lucy has demonstrated her capability in financial planning, payment systems, and directing company growth at various startups and established firms. Her knowledge encompasses investor relations and fundraising, having worked with numerous well-regarded organizations including Amazonia Impact Ventures and GSK.
Lucy Singah's Vision
Reflecting on her appointment, Singah expressed enthusiasm regarding her role during a critical phase in the company’s development. "I look forward to collaborating with the team and leveraging my experience to advance the company's financial goals and drive RTX001 through the clinic," she stated.
Meet the New Chief Business Officer
Daniel Kennedy brings a wealth of business development experience to Resolution Therapeutics, with a notable background in building successful partnerships and leading licensing agreements in the pharmaceutical and biotech sectors. Before this role, Daniel was Vice President of Business Development at Immunocore plc and played a critical role at Achillion Pharmaceuticals until its acquisition by Alexion Pharmaceuticals. His expertise spans multiple areas including global corporate development and marketing.
Daniel Kennedy's Commitment
In response to his new position, Kennedy shared, "I am proud to be joining a company with such a distinguished approach to treat inflammatory and fibrotic diseases. I'm eager to support the company's growth and mission of improving patient care." His extensive background equips him well to further develop Resolution's business capabilities.
Milestone Achievements and Future Endeavors
These appointments coincide with a significant development in Resolution Therapeutics' journey, specifically the recent achievement of dosing the first patient in the Phase I/II EMERALD study, which aims to evaluate the efficacy of RTX001. This clinical trial focuses on patients with end-stage liver disease, marking a major step forward in clinical research and application of regenerative therapies.
About RTX001
RTX001 represents a groundbreaking engineered autologous regenerative macrophage therapy designed to enhance anti-fibrotic and anti-inflammatory responses. This innovative treatment utilizes IL-10-MMP9 mRNA to improve the natural regenerative functions of macrophages, with ongoing studies displaying promising results. As the EMERALD study progresses, researchers aim to establish RTX001 as a transformative treatment for severe liver conditions.
About Resolution Therapeutics
Resolution Therapeutics specializes in developing pioneering regenerative macrophage therapies targeted at inflammatory and fibrotic diseases. The company’s proprietary platform is aimed at creating macrophages with enhanced pro-regenerative properties, offering a new horizon for patient care. With its optimistic outlook, the company plans to employ RTX001 in treating end-stage liver disease while exploring broader indications for various conditions such as graft-vs-host disease and lung fibrosis.
Frequently Asked Questions
What roles did Lucy Singah and Daniel Kennedy assume at Resolution Therapeutics?
Lucy Singah was appointed as Chief Financial Officer (CFO) and Daniel Kennedy as Chief Business Officer (CBO).
What is the significance of the EMERALD study?
The EMERALD study aims to evaluate the efficacy of RTX001 in treating end-stage liver disease, marking a significant achievement for Resolution Therapeutics.
What key experience does Lucy Singah bring to her new role?
Singah has over 20 years of experience in corporate finance and has successfully led financial strategies in both startups and well-established companies.
What is RTX001?
RTX001 is an engineered macrophage therapy targeting inflammatory and fibrotic diseases, currently being studied for its effectiveness in patients with end-stage liver disease.
How does the leadership change impact Resolution Therapeutics' strategy?
The new leadership is expected to steer the company's strategic goals toward enhancing its financial and operational capacities, particularly in the development and commercialization of innovative therapies.
